Company Profile
DanDrit® Biotech A/S is focusing on the research and development of biological products for treatment and control of cancer. DanDrit was founded on the research of Professor Jesper Zeuthen at the Danish Cancer Society (Kraeftens Bekaempelse). Jesper Zeuthen has more than a decade of experience in developing cancer vaccines based on dendritic cells. Dendritic cells are a critical component of the immune system and are necessary for a strong and effective immune response. The ability of dendritic cells to induce a strong immune response is the basis of the vaccine therapies under development at DanDrit. Our expertise in producing dendritic cells from patient blood is combined with conventional production methods to make new and advanced vaccines for cancer patients.
DanDrit's state of the art laboratory facilities are situated in our headquarters at Symbion Science Park in Copenhagen. The aseptic production of sterile vaccines takes place in our GMP-laboratory facilities that have been approved by the Danish Medicines Agency and are inspected regularly.